ALLO - Allogene Therapeutics GAAP EPS of -$0.58 beats by $0.06 revenue of $0.05M beats by $0.04M
- Allogene Therapeutics press release ( NASDAQ: ALLO ): Q3 GAAP EPS of -$0.58 beats by $0.06 .
- Revenue of $0.05M (flat Y/Y) beats by $0.04M .
- The company expects full year GAAP Operating Expenses to be slightly below the low end of its prior guidance of $360 million and $390 million, including estimated non-cash stock-based compensation expense of $90 million to $100 million and excluding any impact from potential business development activities. Cash burn for 2022 is expected to be less than $250 million.
For further details see:
Allogene Therapeutics GAAP EPS of -$0.58 beats by $0.06, revenue of $0.05M beats by $0.04M